In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Ambrx gets $55mm with Series C financing

Executive Summary

Ambrx (optimizes existing protein therapeutics) raised $55mm in a Series C financing led by new investor Apposite. Other first-time backers Glynn Ventures, the Dow Employees' Pension Plan, Scottish Widows Investment, and Union Carbide Employees' Pension Plan were joined by returning shareholders Tavistock Life Sciences, Maverick Capital, 5AM Ventures, Versant Ventures, Aravis Ventures, CMEA Ventures, and Roche Venture Fund. The company will use part of the funds to expand its ReCODE platform for modifying proteins. A member of Apposite has taken a seat on Ambrx's board.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
    • Synthesis Technologies, Production Processes
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies